Nivolumab and Cabozantinib in People with HIV and Advanced Solid Tumors: A Pilot Trial and Systematic Review.
BACKGROUND People living with HIV (PWH) are underrepresented in immune checkpoint inhibitor (ICI) and targeted therapy trials, despite a growing burden of malignancies. Cabozantinib may remodel the tumor microenvironment by reducing immunosuppressive myeloid populations and enhancing cytotoxic T-cell infiltration, ther...